[go: up one dir, main page]

DK1185648T3 - Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst - Google Patents

Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst

Info

Publication number
DK1185648T3
DK1185648T3 DK00941164T DK00941164T DK1185648T3 DK 1185648 T3 DK1185648 T3 DK 1185648T3 DK 00941164 T DK00941164 T DK 00941164T DK 00941164 T DK00941164 T DK 00941164T DK 1185648 T3 DK1185648 T3 DK 1185648T3
Authority
DK
Denmark
Prior art keywords
present
methods
polypeptides
compositions
cell growth
Prior art date
Application number
DK00941164T
Other languages
Danish (da)
English (en)
Inventor
Kevin P Baker
Audrey Goddard
Austin L Gurney
David L Shelton
Victoria Smith
Colin K Watanabe
William I Wood
Caroline Hebert
William Henzel
Rhona C Kabakoff
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/fr
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/fr
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/fr
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/fr
Priority claimed from PCT/US1999/028634 external-priority patent/WO2000036102A2/fr
Priority claimed from PCT/US1999/028551 external-priority patent/WO2000053750A1/fr
Priority claimed from PCT/US1999/030095 external-priority patent/WO2000037640A2/fr
Priority claimed from PCT/US1999/030999 external-priority patent/WO2001005836A1/fr
Priority claimed from PCT/US2000/000376 external-priority patent/WO2000053755A2/fr
Priority claimed from PCT/US2000/003565 external-priority patent/WO2001053486A1/fr
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/fr
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/006319 external-priority patent/WO2000053760A2/fr
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/013705 external-priority patent/WO2000073445A2/fr
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK1185648T3 publication Critical patent/DK1185648T3/da
Application granted granted Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00941164T 1999-06-02 2000-05-30 Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst DK1185648T3 (da)

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
PCT/US1999/012252 WO1999063088A2 (fr) 1998-06-02 1999-06-02 Proteines membranaires et acides nucleiques codant ces proteines
US14065099P 1999-06-22 1999-06-22
US14103799P 1999-06-23 1999-06-23
US14475899P 1999-07-20 1999-07-20
PCT/US1999/020111 WO2000012708A2 (fr) 1998-09-01 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes
PCT/US1999/020594 WO2000015666A2 (fr) 1998-09-10 1999-09-08 Compositions et methodes de traitement des tumeurs
US16250699P 1999-10-29 1999-10-29
PCT/US1999/028313 WO2000032221A2 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
PCT/US1999/028634 WO2000036102A2 (fr) 1998-12-16 1999-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
PCT/US1999/028551 WO2000053750A1 (fr) 1999-03-08 1999-12-02 Compositions et procedes pour le traitement de tumeurs
US17026299P 1999-12-09 1999-12-09
PCT/US1999/030095 WO2000037640A2 (fr) 1998-12-22 1999-12-16 Compositions et methodes de traitement d'une tumeur
PCT/US1999/030999 WO2001005836A1 (fr) 1999-07-20 1999-12-20 Compositions polypeptidiques et methodes de traitement des tumeurs
PCT/US2000/000376 WO2000053755A2 (fr) 1999-03-08 2000-01-06 Compositions et procedes pour le traitement de tumeur
PCT/US2000/003565 WO2001053486A1 (fr) 1999-03-08 2000-02-11 Compositions et procedes destines au traitement de tumeur
PCT/US2000/004341 WO2000053756A2 (fr) 1999-03-08 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
PCT/US2000/004342 WO2000078961A1 (fr) 1999-06-23 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
US18720200P 2000-03-03 2000-03-03
PCT/US2000/006319 WO2000053760A2 (fr) 1999-03-12 2000-03-10 Technique permettant de prevenir la mort des neurones retiniens et traitement des maladies oculaires
PCT/US2000/006884 WO2001005972A1 (fr) 1999-07-20 2000-03-15 Compositions et methodes pour traiter des maladies d'ordre immunologique
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
PCT/US2000/013705 WO2000073445A2 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
PCT/US2000/014941 WO2000073348A2 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses

Publications (1)

Publication Number Publication Date
DK1185648T3 true DK1185648T3 (da) 2007-07-30

Family

ID=40532223

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00941164T DK1185648T3 (da) 1999-06-02 2000-05-30 Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst

Country Status (8)

Country Link
EP (1) EP1185648B1 (fr)
JP (4) JP4145314B2 (fr)
AT (1) ATE357518T1 (fr)
CA (1) CA2373915A1 (fr)
DK (1) DK1185648T3 (fr)
ES (1) ES2287020T3 (fr)
PT (1) PT1185648E (fr)
WO (1) WO2000073348A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066740A2 (fr) * 2000-03-03 2001-09-13 Genentech, Inc. Compositions et methodes de traitement de maladies d'origine immune
US20020192752A1 (en) 1998-09-09 2002-12-19 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6623923B1 (en) 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
EP1715043A3 (fr) * 1998-12-23 2007-01-10 Corixa Corporation Composes destines a l'immunotherapie et au diagnostic du cancer du colon et methodes d'utilisation
CA2479511A1 (fr) * 1999-03-08 2001-07-26 Genentech, Inc. Compositions et procedes destines au traitement de tumeur
CA2384055A1 (fr) * 1999-08-31 2001-03-08 Genentech, Inc. Compositions et procedes pour le traitement de maladies d'ordre immunologique
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001023553A2 (fr) * 1999-09-29 2001-04-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts C4.4a, un nouvel antigène associée à la métastase
AU2608201A (en) * 1999-12-30 2001-07-16 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2001249608A1 (en) * 2000-03-28 2001-10-08 Beth Israel Deaconess Medical Center Bladder cancer-specific peptides for diagnosis and therapy
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US6734289B2 (en) * 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
EP2339028A1 (fr) 2001-09-14 2011-06-29 Clinical Genomics Pty. Ltd Marqueurs d'acides nucléiques pour l'utilisation dans la détermination de la prédisposition au néoplasme et/ou à l'adénome
MXPA04005945A (es) * 2001-12-19 2004-11-01 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
US20060099214A1 (en) * 2002-06-11 2006-05-11 Reinhard Ebner Cancer-linked gene as target for chemotherapy
CA2481507A1 (fr) * 2002-04-16 2003-10-30 Genentech, Inc. Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
AU2003267096B9 (en) * 2002-09-11 2010-11-11 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005032476A2 (fr) * 2003-09-30 2005-04-14 Massachusetts Institute Of Technology Procedes et compositions pour cpg15-2
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
BRPI0514409A (pt) 2004-08-19 2008-06-10 Biogen Idec Inc redobra de proteìnas da famìlia de fator de crescimento transformante beta
US8017576B2 (en) 2005-05-10 2011-09-13 The University Of Chicago Methods and compositions to treat mucositis
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
US7884078B2 (en) 2006-02-10 2011-02-08 Massachusetts Institute Of Technology CPG15 compounds as insulin receptor and insulin-like growth factor receptor agonists
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
KR20110128316A (ko) 2009-02-20 2011-11-29 가니메드 파마슈티칼스 아게 암의 진단 및 치료를 위한 방법 및 조성물
NZ734307A (en) 2009-11-11 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
CN107011440B (zh) 2011-05-13 2021-03-05 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
JP5891561B2 (ja) * 2011-06-03 2016-03-23 学校法人自治医科大学 ミトコンドリア膜タンパク質群およびそれらをコードする遺伝子群
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
CN115197301B (zh) * 2022-06-10 2024-07-16 北京师范大学 用于胞内钙信号检测及相关药物筛选的钙指示工具及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
CA2242633A1 (fr) * 1996-01-04 1997-07-17 Human Genome Sciences, Inc. Facteur transformant de croissance alpha hiii
AU9312198A (en) * 1997-09-17 1999-04-05 Genentech Inc. Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
EP1021532A2 (fr) * 1997-10-08 2000-07-26 Sagami Chemical Research Center Proteines humaines comportant des domaines transmembranaires et adn codant ces proteines
EP1109833A2 (fr) * 1998-09-10 2001-06-27 Genentech, Inc. Compositions et methodes de traitement des tumeurs

Also Published As

Publication number Publication date
JP2006025793A (ja) 2006-02-02
ATE357518T1 (de) 2007-04-15
ES2287020T3 (es) 2007-12-16
JP2007014346A (ja) 2007-01-25
JP4072181B2 (ja) 2008-04-09
WO2000073348A2 (fr) 2000-12-07
PT1185648E (pt) 2007-06-29
JP2007029097A (ja) 2007-02-08
WO2000073348A3 (fr) 2001-07-05
EP1185648A2 (fr) 2002-03-13
EP1185648B1 (fr) 2007-03-21
JP2007029098A (ja) 2007-02-08
JP4145314B2 (ja) 2008-09-03
JP4074645B2 (ja) 2008-04-09
CA2373915A1 (fr) 2000-12-07

Similar Documents

Publication Publication Date Title
DK1185648T3 (da) Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst
DK1484338T3 (da) Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst
ATE537258T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
DK1623989T3 (da) Sammensætninger og fremgangsmåder til diagnosticering af tumorer
WO2002026822A3 (fr) Compositions pumpcn et leurs utilisations
DK1076703T4 (da) Terapeutiske anvendelser af IL-17-homologe polypeptider
ATE397063T1 (de) Fibroblasten-wachstumsfaktor-19
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
WO2000032778A3 (fr) Methodes et compositions permettant d'inhiber la croissance de cellules neoplasiques
ATE439431T1 (de) Zusammenstellung und verfahren zur diagnose von tumoren
WO2001049715A3 (fr) Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
PT1366161E (pt) Anticorpo anatagonista anti-pro842
EP2075335A3 (fr) Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
EP1820860A3 (fr) Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
KR100515857B1 (en) PRO792 Polypeptides
KR100515855B1 (en) PRO351 Polypeptides
EP1277833A3 (fr) Homologue de Costal-2